

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Jenscare Scientific Co., Ltd.**  
**寧波健世科技股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*  
**(Stock Code: 9877)**

**INSIDE INFORMATION**  
**LUX-VALVE REGISTRATION APPLICATION**  
**NOT APPROVED BY THE NMPA**

This announcement is made by Jenscare Scientific Co., Ltd. (the “**Company**”) pursuant to Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (the “**Inside Information Provisions**”) and Rule 13.09(2)(a) of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

After the Company was informed by the Center for Medical Device Evaluation (“**CDME**”) of the National Medical Products Administration (“**NMPA**”) on March 25, 2024 that the technical evaluation for LuX-Valve was not approved at the technical evaluation stage of registration, as at April 24, 2024, the NMPA provided notice that it did not approve the registration application of LuX-Valve.

The LuX-Valve product was recognized by the NMPA as innovation medical device, and was admitted into Special Procedures for Examination and Approval of Innovative Medical Devices (the “**Green Path**”) in 2019, the registration application was submitted to the NMPA in the fourth quarter of 2022 with the results of the one-year clinical trial follow-up. Please refer to the Company’s voluntary announcement published on November 27, 2023 for the clinical trial results of the one-year follow-up of LuX-Valve.

The Company will continue to evaluate the impact of the NMPA’s decision and advance the global commercialization process of LuX-Valve series products, including but not limited to obtaining the registration approval from NMPA for LuX-Valve Plus as soon as possible, completing registration clinical trial and obtaining registration approval for CE Certificate, completing the Early Feasibility Study and subsequent clinical study and obtaining registration approval in the U.S., as well as conducting pre-commercial activities in multiple countries and regions, so as to benefit the patients with tricuspid regurgitation worldwide. The Company remains confident in the clinical benefits and commercial potential of LuX-Valve series products.

Meanwhile, the Company will make prudent and timely operational optimization to ensure the smooth operation and long-term sustainable development of the Company's business. The Company will make further announcement relating to matters set out in this announcement in due course as and where necessary.

**Cautionary Statement as required by Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: There is no assurance that the Company will ultimately develop, market and/or commercialize LuX-Valve successfully. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.**

By order of the Board  
**Jenscare Scientific Co., Ltd.**  
**Mr. LV Shiwen**  
*Chairman and Executive Director*

Hong Kong, April 25, 2024

*As at the date of this announcement, the executive Directors are Mr. LV Shiwen and Mr. PAN Fei; the non-executive Directors are Mr. TAN Ching, Mr. ZHENG Jiaqi, Ms. XIE Youpei and Mr. CHEN Xinxing; and the independent non-executive Directors are Dr. LIN Shoukang, Ms. DU Jiliu and Dr. MEI Lehe.*